Source: China – South China Morning PostChina has moved a step closer to developing a home-grown mRNA vaccine against Covid-19, with the publication of early trial results for its prime candidate ARCoV.No serious adverse events were recorded in the phase 1 clinical trial data, published last week by The Lancet Microbe, but scientists said it was too early to judge its success.Large-scale trials of the vaccine – jointly developed by the Academy of Military Science, Walvax Biotechnology and Suzhou Abogen Biosciences – have been delayed…Read More